Epitan plans AIM listing
Thursday, 31 March, 2005
Melbourne's Epitan is planning to raise up to 15 million pounds (AUD$37 million) in a flotation on London's AIM stock market. EpiTan focuses on dermatology and its main product, Melanotan, helps treat sunburn injury.
The company said its London flotation would raise money to fund further development of Melanotan and increase its international profile. EpiTan is already listed on the Australian stock exchange.
"I am delighted to be able to introduce EpiTan to UK investors, particularly as we expect Europe to be a key market for our lead development product, Melanotan," said chief executive Iain Kirkwood.
Trading in the shares on AIM is due to begin in May. Investment bank Teather & Greenwood is the broker and adviser on the flotation.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
